**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 6143**

**Columns: TOPIC HIGHLIGHTS**

WJG 20th Anniversary Special Issues (2): Hepatitis C virus

**Hepatitis C virus reactivation in cancer patients in the era of targeted therapies**

Yazici O *et al.* Hepatitis C reactivation and targeted therapies

Ozan Yazici, Mehmet Ali Nahit Şendur, Sercan Aksoy

**OzanYazici, Mehmet Ali Nahit Şendur,** Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara06100, Turkey

**Sercan Aksoy,** Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06100, Turkey

**Author contributions:** Yazici O wrote the manuscript and was also involved in the editing process; Nahit Şendur MA provided articles related to the issue and was also involved in editing the manuscript; Aksoy S analyzed the reports and selected the papers that were considered relevant for the aim of this review and was involved in editing of the manuscript.

**Correspondence to: SercanAksoy, MD,** Department of Medical Oncology**,** Hacettepe University Cancer Institute, Hacettepe Mh, Sihhiye Ankara 06100, Turkey. saksoy07@yahoo.com

**Telephone**: +90-312-3052954 **Fax**: +90-312-3242009

**Received:** October 4, 2013 **Revised:** December 26, 2013

**Accepted:** March 5, 2014

**Published online:**

**Abstract**

The purpose of this review is to summarize evidence of hepatitis C reactivation in cancer patients in the era of targeted therapies. Targeted therapies are novel therapeutics that is frequently used in cancer patients. During treatment with targeted therapies, viral replication is one of the major problems that can occur. The PubMed database, ASCO and ASCO Gastrointestinal Cancer Symposium abstracts were searched up until September 15, 2013 using the following search keywords “targeted therapies, rituximab, alemtuzumab, brentixumab, hepatitis, hepatitis C reactivation, tyrosine kinase inhibitors, imatinib, mammalian target of rapamycin (mTOR) inhibitors, everolimus, anti-HER therapies, trastuzumab, pertuzumab, lapatinib, anti-EGFR therapies, cetuximab, panitumumab, and ipilimumab“. Papers considered relevant for the aim of this review were selected by the authors. The data about rituximab induced hepatic flare in hepatitis C virus (HCV) positive patients is controversial. However, there is the possibility of life threatening hepatic flare that can develop after HCV ribonucleic acid (HCV-RNA) viral load increases. Routine follow-up of liver function tests should be advised. Especially in high-risk patients, such as patients with baseline chronic active hepatitis and cirrhosis and where there are plans to administer rituximab concomitantly with corticosteroids, it is advised to have close follow-up of HCV viral load. The data is insufficient to make accurate statements about the association of alemtuzumab therapy and HCV reactivation. However, alemtuzumab may cause deep immunosuppression. Due to this, it is better to follow up with liver function tests and HCV RNA levels during alemtuzumab therapy. Brentixumab has effects on antibody dependent cellular toxicity and may decrease humoral immunity. Thus, we believe that during brentixumab treatment of HCV infected patients, clinicians may encounter hepatitis C reactivation. There have been no reported cases of hepatitis C reactivation with imatinib therapy. However, there are many reports of Hepatitis B reactivation with imatinib treatment. Based on the evidence of hepatitis B reactivation with imatinib and the effects of imatinib on immune system functions, we suggest that imatinib therapy might be a risk factor for HCV reactivation. Anti-human epidermal growth factor receptor 2 (HER2) therapies are not associated with hepatic flare in HCV infected patients. Post-transplant studies reported that mTOR was safely administered to patients with active hepatitis C without causing hepatic flare. Cetuximab and panitumumab have not been associated with HCV reactivation. Two cases of HCV infected melanoma were safely treated with ipilimumab without any HCV reactivation and hepatic flare. Targeted therapies are a new emerging area of oncology treatment modalities. While treating HCV infected cancer patients, clinicians should be careful of the immune suppressive properties of targeted therapies. Further, randomized trials are needed to establish algorithms for this issue.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key Words:** Hepatitis C; Hepatitis C reactivation; Monoclonal antibodies; Cancer, Rituximab

**Core tip:** During treatment with targeted therapies, especially with monoclonal antibodies, viral replication is one of the major problems for cancer patients. Especially in high risk patients, such as patients with baseline chronic active hepatitis and cirrhosis and where there are plans to administer rituximab concomitantly with corticosteroids, it is advised to have close follow-up of hepatitis C virus (HCV) viral loadand to perform liver function tests. During alemtuzumab therapy we also advise to follow liver function tests and HCV RNA levels. In the course of imatinib therapy, clinicians should follow liver function alterations. Anti-HER2, anti-EGFR and immunmodulating therapies can be safely used in HCV positive patients.

Yazici O, Şendur MA, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.

*World J Gastroenterol* 2013;

**Available from:**

**DOI:**

**INTRODUCTION**

Viral hepatitis reactivation is one of the major challenges encountered during a variety of chemotherapy treatments. In the literature, there is a well-established association between hepatitis B virus (HBV) reactivation and some anti-cancer drugs, especially monoclonal antibodies[1-5]. On the other hand, there is limited data concerning the reactivation of HCV with chemotherapeutic drugs and targeted therapies. In this review, we aimed to outline the evidence of hepatitis C reactivation in the era of targeted therapies.

Currently, many oncologists encounter patients treated with chemotherapy regimens consisting of targeted therapies. Therefore, it is important to deal with the side effects of these therapies. During treatment with targeted therapies, especially monoclonal antibodies, viral replication is one of major problems for cancer patients. The reactivation of hepatitis viruses has potentially fatal complications, which have to be followed closely and carefully. HBV replication is strongly associated with anti-Cluster of Differentiation 20 (CD20) monoclonal antibody containing chemotherapy regimens. However, only a few studies have investigated the occurrence of hepatitis C virus (HCV) reactivation during immunosuppressive treatments. As we know from the data of transplant patients, HCV RNA negative solid organ transplants did not demonstrate HCV replication in plasma, liver or peripheral blood mononuclear cells with long-term immunosuppressive treatment[6]. Hepatitis is described as more than a threefold increase in the upper limit of normal serum alanine aminotransferase (ALT) levels on two consecutive examinations. Most chronic hepatitis C patients have stable HCV RNA levels over a long time period, which may be altered not more than 0.5 logs. In this context, hepatitis C reactivation can be defined as an increase of HCV-RNA viral load greater than 1 log10 IU/mL and/or at least a threefold increase in serum ALT in HCV infected patients[7,8].

Hepatitis C virus is one of the leading causes of chronic hepatitis, cirrhosis and hepatocellular carcinoma[9]. There has been a widely accepted theory related to HCV replication with immunosuppressive treatment[10,11]. According to this theory, Hepatitis C reactivation with immunosuppressive therapy can be divided into three phases. In the first phase, an increase in HCV replication in hepatic cells causes cell-mediated immunoreactions. After discontinuation of treatment, the immune system is fully restored. In the third phase, called the recovery phase, liver functions recover and HBV markers return to baseline levels[12]. We will discuss the issue of HCV reactivation according to subtypes of targeted therapies in the section below.

**MONOCLONAL ANTIBODIES AGAINST CLUSTER OF DIFFERENTIATION**

***Rituximab***

Rituximab is a chimeric mouse-human antibody (IgG1) that reacts against CD20 antigens expressed on pre-B and mature lymphocytes. By causing B cell depletion, rituximab induces humoral immunity dysfunction, may affect T cell activation and also can cause dysfunction of cellular cytotoxicity[13]. Rituximab was the first monoclonal antibody approved by the Food and Drug Administration and is the most widely used treatment for CD20 positive B cell lymphoma patients[14]. As a result of rituximab treatment, B cell depletion occurs within 24-48 h following the first infusion. After completion of rituximab therapy, nearly 6-9 mo are needed for B cell recovery. This may render patients at high risk of infection. In many studies, it has been demonstrated that HCV infected B cell lymphoma patients had more frequent hepatitis than non-infected controls[15]. In contrast, some studies showed only increased HCV viral load but not concomitantly increased liver function tests. One of these reports, by Aksoy and colleagues, evaluated a case of a HCV infected Non-Hodgkin Lymphoma (NHL) patient treated with rituximab monotherapy for three consecutive weeks. During rituximab therapy, HCV RNA viral load gradually increased without a significant increase in liver function tests[16]. In another study, the researchers monitored HCV-RNA levels of five HCV-antibody (ab) positive NHL patients treated with rituximab. They observed an increased HCV RNA viral load during and after chemotherapy in all five patients, but only one had a significant increase in liver function tests[17]. In a study from Italy, 156 consecutive HCV infected patients with NHL were retrospectively evaluated. None of the patients had antiviral therapy. In this retrospective cohort, thirty-five patients were administered rituximab-containing regimens. Five out of 35 patients had a mild increase in liver function tests, which did not cause therapy interruption[18].

Nosotti and colleagues showed that HCV infected NHL patients had hepatic flares while treated with regimens containing rituximab. In this study, ALT and bilirubin were monitored every 2 wk and monthly for at least 12 mo after completion of chemotherapy and HCV RNA was monitored every month in HCV positive NHL patients. Hepatic flare is defined as a 5 fold increase, according to the criteria of National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0. HCV-positive patients had a 12 fold relative risk of developing liver dysfunction compared to a HCV-negative group (*P* < 0.001). The patients who did not receive rituximab did not develop liver dysfunction. Some patients had hepatic flares during therapy (*n* = 3) and two others had flares after completion of therapy, which may be a consequence of different mechanisms of hepatic damage. Three patients had concurrently increased ALT and HCV RNA, whereas 2 patients showed a HCV RNA increase before the rise of ALT. Hepatic flares in this study did not develop a clinically important problem and none of the patient treatment regimens were stopped or changed due to liver dysfunction[19]. In the trial of Nosotti and colleagues, no correlation was found between increased ALT and HCV RNA during hepatic flares[19]. Besides Hepatitis B and C, rituximab containing regimens may cause reactivation of many viral diseases, such as cytomegalovirus, parvovirus B19, echo virus, and varicella-zoster virus[20]. On the other hand, in the cohort of Ennishi and colleagues, only one case had elevated liver enzymes with rituximab therapy. In this case, while liver function tests increased, HCV RNA levels decreased. This suggests to us that the cause of liver damage was an immune reaction against hepatocytes with HCV. This study could not demonstrate any association between increased viral load and hepatic dysfunction[17]. In one single center experience, 4 patients infected with HCV with a diagnosis of NHL were treated with rituximab containing regimens. HCV-RNA and HCV antibody titers were analyzed. They found that after post-rituximab administration, HCV IgG antibodies in all four patients decreased slightly throughout the clinical course. Rituximab induced B cell depletion for many months, but HCV RNA load did not remain elevated. As a result, we think that B cell depletion was not the only reason for the elevated HCV RNA level. Data about the pathogenesis of rituximab induced HCV reactivation is controversial. As a consequence of B cell depletion, IgG antibody titers decrease, which may lead to viral evasion from the immune system and cause accelerated viral replication[21]. Another explanation was obtained from lupus studies. One lupus study demonstrated that regulatory T cells increased within 30 days of rituximab administration, but after the 30th day suddenly T cell apoptosis increased and the number of T cells decreased within 90 d[22]. Decreased numbers of T cells suggest that this decreased amount may have not been enough for suppression of HCV viruses. On the other hand, another study from Italy did not find any association between rituximab administration and HCV reactivation[18]. A third explanation for the association between HCV reactivation and rituximab therapy is that HCV particles are carried by B-lymphocytes of HCV infected patients and after destruction with rituximab these particles disperse to the whole body[23]. In another study, 104 consecutive patients with NHL, who had no antiviral treatment, were retrospectively evaluated. This study aimed to evaluate the liver related effects of rituximab on HCV-infected NHL patients. All patients were screened for HCV serum antibodies. HCV antibody positive patients were further examined for HCV RNA levels and HCV genotyping. Nine out of 104 patients were HCV positive prior to rituximab-containing regimens. Hepatic flare was defined as an ALT increase > 5 times the upper limit of normal. Three of the HCV-Ab positive patients had hepatic flares and at the same time slightly increased HCV RNA viral load compared to HCV-Ab negative patients, none of whom had hepatic flares. The difference was statistically significant (*P* < 0.001). However, no correlation was detected between ALT and levels of HCV-RNA. Until now, there has not been any randomized placebo controlled studies. The results thus far have been from single center institution experiences and small studies. For instance, Dizdar and colleagues reported that patients with high baseline HCV RNA load might have a mortality rate up to 45% after rituximab containing therapy[24]. The study from Italy evaluated 8 HCV infected onco-hematological malignancies. Seven of the patients had rituximab containing regimens and all of these patients had at least a 1.5 log IU/mL increase of HCV RNA level. Hepatic flare was detected after discontinuation of rituximab, possibly due to cell mediated immunological response against HCV infected hepatocytes. One cirrhotic patient had a life threatening hepatic flare[25]. Also, these interesting results were supported by the results of one cryoglobulinemia patient who had two cycles of rituximab. After discontinuation of rituximab, the hepatic flare observed in this patient coincided with a reappearance of B cells and a HCV RNA decline, suggesting a role of antibody dependent cellular cytotoxicity[26].

In conclusion, the evidence concerning hepatic flare in HCV infected patients undergoing rituximab therapy are inconsistent. However, there is the possibility of life threatening hepatic flare that can develop after a HCV-RNA viral load increase. Therefore, routine follow-up of liver function tests should be recommended. Especially in high-risk patients, such as those with chronic active hepatitis and cirrhosis, and where it is planned to administer rituximab concomitantly with corticosteroids and chemotherapy regimens, patients should be closely monitored for HCV RNA levels. For HCV infected lymphoma patients, as also suggested in recent studies[27, 28], prior to rituximab therapy we advise considering anti-hepatitis C virus treatment on an individual basis.

***Alemtuzumab***

Alemtuzumab is a human monoclonal antibody against CD52 receptors localized on lymphoid cells[29]. It fixes complements and causes antibody dependent cellular cytotoxicity. Thus, alemtuzumab depletes normal and malignant T and B lymphocytes and causes deep immunosuppression[30]. It can be used alone or in combination with chemotherapy regimens for the treatment of patients with refractory chronic lymphocytic leukemia (CLL) with poor prognostic factors. In the literature, it was firstly reported that two CLL patients with occult hepatitis B infection, following alemtuzumab therapy developed virological and biochemical hepatic flare[31]. After publication of the first cases of Hepatitis B reactivation with alemtuzumab, the first case of hepatitis C reactivation was reported[24]. This case was CLL, who had severe hepatitis due to reactivation of HCV following treatment with a combination of alemtuzumab and methylprednisolone. This was a case of relapsed CLL, who was anti HCV IgG positive and HCV RNA negative. Liver function tests were within normal limits prior to alemtuzumab therapy. Thirty-four days after the first dose of alemtuzumab and prednisolone, a rapid rise of ALT and gamma glutamyltransferase was detected. Concurrently, HCV RNA viral load increased to > 106 copies/mL. Immediately after discontinuation of alemtuzumab therapy, ribavirin 600 mg orally twice daily and interferon alfa-2a 180 mcg subcutaneously once weekly was started. However, HCV RNA copies continued to fluctuate and never returned to normal levels[32].

 In conclusion, the data is insufficient to offer clear advice concerning the effect of alemtuzumab therapy on HCV infected lymphoma patients. However, as alemtuzumab causes deep immunosuppression, like all other immune response modifiers, during alemtuzumab therapy of HCV infected patients we advise to follow liver function tests and HCV RNA levels.

# *Brentixumab*

Brentuximab vedotin is another monoclonal antibody against CD30 on lymphocytes, conjugated with the anti-microtubule agent monomethylauristatin. CD30 can be found on malignant lymphoid cells and activated T cells. CD30 has an important role in developing memory and effector CD4+ T cells but effects on B cells are controversial. However, mouse studies demonstrated that CD30L/CD30 interactions cause an increased humoral immune response[33]. Following binding to CD30, brentuximab vedotin is rapidly internalized and leads to cell cycle arrest and apoptosis. Brentixumab has been used in relapsed/refractory Hodgkin lymphoma and CD30-positive lymphoproliferative disorders[34]. In the literature, there has been no reported case of viral hepatitis reactivation with brentuximab treatment, but brentixumab may affect antibody dependent cellular toxicity and may decrease humoral immunity. Thus, we believe that during brentixumab treatment of HCV infected patients, clinicians may encounter hepatitis C reactivation. For further comments on this issue, we will have to wait for an accumulation of experience with brentixumab administration.

**TYROSINE KINASE INHIBITORS**

Tyrosine kinase inhibitors group consist of many different drugs. Some tyrosine kinase inhibitors, especially sunitinib, sorafenib, and pazopanib, still have no reported association with viral hepatitis reactivation in the literature. In a phase 3 trial, sorafenib or sunitinib was administered to hepatocellular carcinoma patients. In this study most of the patients were HBV or HCV positive prior to diagnosis of hepatocellular carcinoma. During treatment, only one patient (0.2%) in the sunitinib arm and three (0.6%) patients in the sorafenib arm had hepatic failure. HCV and HBV infected patients safely used sunitinib or sorafenib without clinically significant hepatitis C reactivation[35]. However, up to now sorafenib-induced liver failure has been reported in two patients with a diagnosis of thyroid cancer[36,37]. Although hepatic failure associated with sorafenib treatment is rare, in HCV infected patients the possible development of sorafenib induced hepatic flare must be kept in mind. On the other hand, HCV virus uses some tyrosine kinase pathways during their replication process[38]. Therefore, some TKI's may have a suppressive role on HCV replication. For example, one in vitro study demonstrated that sorafenib efficiently blocks HCV replication *in vitro*[39].

Pazopanib is another multikinase inhibitor used in the treatment of advanced renal cell cancer and different types of sarcomas. In a phase 3 trial of pazopanib in advanced renal cell carcinoma patients, the most commonly detected laboratory abnormality was elevated ALT and AST. However, most of the elevations in liver function tests were asymptomatic and irreversible[40]. There has been no reported hepatitis related to axitinib treatment[41]. We think that pazopanib and axitinib can be safely used in HCV infected cancer patients. Crizotinib is a novel multi-targeting tyrosine kinase inhibitor. One case report showed acute hepatitis with crizotinib therapy in a dose dependent manner[42]. From this point of view, we should keep in mind that in HCV infected patients, crizotinib induced liver injury may cause a high risk of mortality. We will focus on imatinib, which was reported in the literature as causing viral hepatitis reactivation.

***Imatinib***

Imatinibmesylate is a well-known tyrosine kinase inhibitor of the BCR-ABL fusion gene product and is generally used for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors. Still, there has been no reported case of hepatitis C reactivation under imatinib therapy. However, there were many reports of Hepatitis B reactivation in CML patients[43-46]. Interestingly, for none of the gastrointestinal stromal tumor patients was it reported that they had viral hepatitis B reactivation. Except for CML, only one case of desmoid tumor had hepatitis B reactivation during imatinib treatment. The reason imatinib induces reactivation is unclear, but in vitro studies have shown that imatinib can inhibit T-cell activation and proliferation[47]. The explanation is that there is an impairment of differentiation of progenitor stem cells to dendritic cells by imatinib, and as a consequence there is a defective immune response[48]. Two of the reported cases by Guan-Min and et al. support the hypothesis of the immune restoration stage of HBV reactivation[46]. Clinicians should follow up HBV DNA and liver function tests of HBV infected patients during imatinib treatment. There has been no clear data about hepatitis C reactivation. Only one case report has shown that a HCV-positive CML patient with molecular remission did not develop any clinically important hepatic flare[49]. In a phase II study, HCV and HBV infected hepatocellular carcinoma patients were treated with imatinib and no clinically relevant hepatic flare occurred as a treatment complication, but only one patient had grade 3 ALT elevation in this study. In this trial, imatinib was safely used in HCV and HBV infected patients[50]. These data are insufficient to make a correct interpretation. However, based on the evidence of hepatitis B reactivation with imatinib and effects of imatinib on immune system functions, we think that imatinib therapy might be a risk factor for HCV reactivation in infected patients. Therefore, during imatinib treatment of HCV infected patients, clinicians should be alert and carefully follow liver function alterations.

**MAMMALIAN TARGET of RAPAMYCIN (mTOR) INHIBITORS**

The well-known mTOR inhibitor is everolimus, approved in renal carcinoma, neuroendocrine tumors and breast cancer. Inhibition of mTOR blocks interleukin 2 and nuclear factor-kappa signaling. Therefore, mTOR inhibitors have anticancer and immunosuppressive properties, which can cause various infections[51]. Teng and colleagues reported that activation of the mTOR pathway in HBV infected hepatocytes may feedback suppress HBV surface antigen synthesis. According to this report, mTOR inhibitor therapies may potentially activate HBV replication[52]. In a clinical trial of everolimus, one patient died due to HBV reactivation. Until now, in the literature two patients with renal cell cancer were reported to have hepatitis B reactivation associated with everolimus treatment[53,54]. In a phase 3 study, which investigated the efficacy of everolimus in breast cancer patients, the first case of everolimus related HCV reactivation was reported[55]. Most of our knowledge about the experience of everolimus administration to HCV infected patients depends on transplant studies. One of these studies demonstrated that three recurrent hepatitis C patients after liver transplantation were treated with everolimus as a post-transplant immunosuppressive agent. In this study, none of these patients had hepatitis C progression, and also clinical, biochemical, as well as histological parameters were stabilized[56]. Another post-transplant study also included relapsed HCV infections, and demonstrated that everolimus can be used safely without HCV reactivation in long-term post-transplant patients[57]. Temsirolimus is another mTOR inhibitor used for advanced renal cell carcinoma. It has similar immunosuppressive and anti-cancer properties as everolimus. The use of temsirolimus may cause immunosuppression and an increased risk of infections[58]. To our knowledge, no case of viral hepatitis reactivation related to the use of temsirolimus has been reported in the literature. Although these are post-transplant studies, we should emphasize that mTOR activity is critical for the anti-hepatitis C virus action of interferon[59]. Therefore, we can speculate that mTOR inhibitors may induce HCV replication in HCV infected patients by blocking mTOR activity.

**ANTI-HER-2 AND ANTI-EGFR MONOCLONAL ANTIBODIES**

Trastuzumab is a monoclonal antibody against HER-2 (also known as ErbB-2). Single center experience reported the results of 10 breast cancer patients infected with HCV. Among 10 patients who received chemotherapy, two received only trastuzumab and two received combination therapy of trastuzumab and cytotoxic chemotherapy. This study demonstrated no clinically meaningful changes in HCV-RNA viral load or increased liver enzymes in breast cancer patients receiving chemotherapy and/or trastuzumab[60]. One interesting case report had decreased HCV RNA levels with trastuzumab therapy. In this editorial it was suggested that epidermal growth factor signaling might be biologically relevant for HCV[61]. In the literature, there has been no report related to pertuzumab and lapatinib associated with hepatic flare in HCV infected cancer patients. In summary, it seems to be safe to administer anti-HER2 therapies to HCV infected patients.

Cetuximab and panitumumab are two monoclonal antibodies against epidermal growth factor receptor (EGFR) receptor. There has been no association with HCV reactivation. However, there has been interesting data about the EGFR and hepatitis C virus. EGFR has been shown to be important in the entry process for HCV[62,63]. HCV infection has been shown to result in EGFR activation. Lupberger and et al. reported that in HCV infected patients, IFN-alfa and the EGFR inhibitor erlotinib potentiate the anti-viral effect in a synergistic manner[64].

**IMMUNMODULATING MONOCLONAL ANTIBODIES**

Ipilimumab is a recombinant monoclonal antibody that blocks the action of negative T cell regulator cytotoxic T-lymphocyte associated antigen 4 (CTLA4). Therefore, ipilimumab causes T cell activation and proliferation. Immune mediated hepatitis is a well-known side effect of ipilimumab treatment. CTLA4 pathways have a role in the exhaustion of HCV specific T cells in HCV infected patients[65]. One of the well-known side effects of ipilimumab is autoimmune hepatitis. However, until now, two cases of HCV infected melanoma patients have been safely treated with ipilimumab without any HCV reactivation and hepatic flare. Also one of these case reports showed decreased viral load during ipilumumab treatment[66,67].

**CONCLUSION**

Hepatitis C reactivation is one of the major challenges during treatment of HCV infected cancer patients. Targeted therapies are a new emerging area in cancer treatment and may interfere with normal immune system function and by this may cause reactivation of viral hepatitis. We should consider HCV reactivation during treatment with targeted therapies in HCV infected patients (Table 1).

It is clear that an increased HCV viral load is caused by rituximab therapy in HCV infected patients. However, the increased viral load is not directly associated with hepatic flares. The pathogenesis of rituximab induced hepatic flares needs to be investigated in further randomized studies. However, there is the possibility of having life threatening hepatic flares during and after rituximab therapy. In this context, we strongly recommend close follow-up with liver function tests, especially in patients who have baseline active hepatitis or cirrhosis. In addition, if it is planned to administer corticosteroids to patients concomitantly with rituximab, we recommend close monitoring of HCV RNA levels. Anti-HCV treatment should be considered on an individual base before rituximab therapy. Alemtuzumab is another monoclonal antibody against CD52 that can cause deep immunosuppression like all other immune response modifiers. We advise testing of liver function and HCV RNA levels for HCV infected patients receiving alemtuzumab therapy. Brentixumab is an anti-CD 30 antibody and may cause hepatitis C reactivation in HCV infected patients. Further evidence is needed to make comments on brentixumab.

As a group, tyrosine kinase inhibitors do not cause HCV reactivation. However, imatinib mesylate, the most widely used tyrosine kinase inhibitor, has been associated with HBV reactivation. Based on this information, we think that imatinib therapy might be a risk factor for reactivation of HCV infected patients. Therefore, clinicians should be alert and carefully follow liver function alterations during imatinib treatment of HCV infected patients. mTOR inhibitors have immunosuppressive properties, but only in one phase 3 study was everolimus related HCV reactivation reported as a side effect. In contrast, post-transplant studies demonstrated that everolimus could be safely used in HCV infected patients. Anti-HER2 and anti-EGFR therapies can be safely used in HCV infected patients. To our knowledge, two cases of HCV infected melanoma patients were safely treated with ipilimumab without any HCV reactivation or hepatic flare.

Targeted therapies are a new emerging area of oncology treatment modalities. When treating HCV infected cancer patients, clinicians should be careful about the immune suppressive properties of targeted therapies. Further, randomized trials are needed to establish algorithms for this issue.

**P-Reviewers: Clement J, Mazzanti R, Raboni SM, Shih WL S-Editor** Qi Y

**L-Editor E-Editor**

**REFERENCES**

1 **Wang F**, Xu RH, Luo HY, Zhang DS, Jiang WQ, Huang HQ, Sun XF, Xia ZJ, Guan ZZ. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. *BMC Cancer* 2008; **8**: 115 [PMID: 18433487 DOI: 10.1186/1471-2407-8-115]

2 **Dervite I**, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. *N Engl J Med* 2001; **344**: 68-69 [PMID: 11187122 DOI: 10.1056/NEJM200101043440120]

3 **Yeo W**, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. *J Clin Oncol* 2009; **27**: 605-611 [PMID: 19075267 DOI: 10.1200/JCO.2008.18.0182]

4 **Manzano-Alonso ML**, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. *World J Gastroenterol* 2011; **17**: 1531-1537 [PMID: 21472116 DOI: 10.3748/wjg.v17.i12.]

5 **Wang Y**, Luo XM, Yang D, Zhang J, Zhuo HY, Zhang J, Jiang Y. Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study. *World J Gastroenterol* 2013; **19**: 923-930 [PMID: 23429298 DOI: 10.3748/wjg.v19.i6.923.]

6 **Nicot F**, Kamar N, Mariamé B, Rostaing L, Pasquier C, Izopet J. No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. *Transpl Int* 2010; **23**: 594-601 [PMID: 20002658 DOI: 10.1111/j.1432-2277.2009.01025.x]

7 **Nguyen TT**, Sedghi-Vaziri A, Wilkes LB, Mondala T, Pockros PJ, Lindsay KL, McHutchison JG. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. *J Viral Hepat* 1996; **3**: 75-78 [PMID: 8811641 DOI: 10.1111/j.1365-2893.1996.tb00084.x]

8 **Fanning L**, Kenny-Walsh E, Levis J, Choudhury KR, Cannon B, Sheehan M, Whelton M, Shanahan F. Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. *Hepatology* 2000; **31**: 225-229 [PMID: 10613750. DOI:10.1111/j.1365-2893.1996.tb00084.x]

9 National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. *Hepatology* 1997; **26**: 2S-10S [PMID: 9305656 DOI: 10.1002/hep.510260701]

10 **Vento S**, Cainelli F, Mirandola F, Cosco L, Di Perri G, Solbiati M, Ferraro T, Concia E. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. *Lancet* 1996; **347**: 92-93 [PMID: 8538348 DOI: 10.1016/S0140-6736(96)90212-3]

11 **Takai S**, Tsurumi H, Ando K, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Takahashi T, Oyama M, Onishi H, Tomita E, Takami T, Imawari M, Moriwaki H. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. *Eur J Haematol* 2005; **74**: 158-165 [PMID: 15654908 DOI: 10.1111/j.1600-0609.2004.00376.x]

12 **Watanabe T**, Tanaka Y. Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. *Hepatol Res* 2013; **43**: 113-121 [PMID: 23186317 DOI: 10.1111/hepr.12014]

13 **Eisenberg R**, Looney RJ. The therapeutic potential of anti-CD20 "what do B-cells do?". *Clin Immunol* 2005; **117**: 207-213 [PMID: 16169773 DOI: 10.1016/j.clim.2005.08.006]

14 **Leget GA**, Czuczman MS. Use of rituximab, the new FDA-approved antibody. *Curr Opin Oncol* 1998; **10**: 548-551 [PMID: 9818234 DOI: 10.1097/00001622-199811000-00012]

15 **Ennishi D**, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y, Sunami K, Miyata A, Murayama K, Sakai A, Matsumoto M, Shinagawa K, Takaki A, Matsuo K, Kinoshita T, Tanimoto M. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. *Blood* 2010; **116**: 5119-5125 [PMID: 20823454 DOI: 10.1182/blood-2010-06-289231]

16 **Aksoy S**, Abali H, Kilickap S, Erman M, Kars A. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. *Clin Lab Haematol* 2006; **28**: 211-214 [PMID: 16706940 DOI: 10.1111/j.1365-2257.2006.00779.x]

17 **Ennishi D**, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, Okamoto H, Tanimoto M, Hatake K. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. *Am J Hematol* 2008; **83**: 59-62 [PMID: 17712791 DOI: 10.1002/ajh.21022]

18 **Visco C**, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, Bonoldi E, Chilosi M, Viglio A, Lazzarino M, Pizzolo G, Rodeghiero F. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. *Ann Oncol* 2006; **17**: 1434-1440 [PMID: 16766591 DOI: 10.1093/annonc/mdl131]

19 **Nosotti L**, D'Andrea M, Pitidis A, Pimpinelli F, Dessanti ML, Pisani F, Vignally P, Petti MC. Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy. *Scand J Infect Dis* 2012; **44**: 70-73 [PMID: 21905952 DOI: 10.3109/00365548.2011.611819]

20 **Aksoy S**, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, Barista I. Rituximab-related viral infections in lymphoma patients. *Leuk Lymphoma* 2007; **48**: 1307-1312 [PMID: 17613758 DOI: 10.1080/10428190701411441]

21 **Cerny A**, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. *Hepatology* 1999; **30**: 595-601 [PMID: 10462362 DOI: 10.1002/hep.510300312]

22 **Vigna-Perez M**, Hernández-Castro B, Paredes-Saharopulos O, Portales-Pérez D, Baranda L, Abud-Mendoza C, González-Amaro R. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. *Arthritis Res Ther* 2006; **8**: R83 [PMID: 16677395 DOI: 10.1186/ar1954]

23 **Dammacco F**, Sansonno D, Piccoli C, Racanelli V, D'Amore FP, Lauletta G. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. *Semin Liver Dis* 2000; **20**: 143-157 [PMID: 10946420 DOI: 10.1055/s-2000-9613]

24 **Dizdar O**, Tapan U, Aksoy S, Harputluoglu H, Kilickap S, Barista I. Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C. *Eur J Haematol* 2008; **80**: 381-385 [PMID: 18221389 DOI: 10.1111/j.1600-0609.2008.01039.x]

25 **Coppola N**, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, Sagnelli C, Ferrara MG, Sagnelli E. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. *Dig Liver Dis* 2012; **44**: 49-54 [PMID: 21885355 DOI: 10.1016/j.dld.2011.07.016]

26 **Lake-Bakaar G**, Dustin L, McKeating J, Newton K, Freeman V, Frost SD. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. *Blood* 2007; **109**: 845-846 [PMID: 17210867 DOI: 10.1182/blood-2006-08-041525]

27 **Vallisa D**, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, Lazzaro A, Trabacchi E, Anselmi E, Arcari AL, Moroni C, Bertè R, Lazzarino M, Cavanna L. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. *J Clin Oncol* 2005; **23**: 468-473 [PMID: 15659492 DOI: 10.1200/JCO.2005.06.008]

28 **Mazzaro C**, De Re V, Spina M, Dal Maso L, Festini G, Comar C, Tirelli U, Pozzato G. Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. *Br J Haematol* 2009; **145**: 255-257 [PMID: 19239472 DOI: 10.1111/j.1365-2141.2008.07565.x]

29 **Yeo W**, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. *Hepatology* 2006; **43**: 209-220 [PMID: 16440366 DOI: 10.1002/hep.21051]

30 **Osterborg A**, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. *J Clin Oncol* 1997; **15**: 1567-1574 [PMID: 9193354]

31 **Iannitto E**, Minardi V, Calvaruso G, Mulè A, Ammatuna E, Di Trapani R, Ferraro D, Abbadessa V, Craxí A, Di Stefano R. Hepatitis B virus reactivation and alemtuzumab therapy. *Eur J Haematol* 2005; **74**: 254-258 [PMID: 15693796 DOI: 10.1111/j.1600-0609.2004.00375.x]

32 **Anoop P**, Wotherspoon A, Matutes E. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia. *Br J Haematol* 2010; **148**: 484-486 [PMID: 19874308 DOI: 10.1111/j.1365-2141.2009.07972.x]

33 **Kennedy MK**, Willis CR, Armitage RJ. Deciphering CD30 ligand biology and its role in humoral immunity. *Immunology* 2006; **118**: 143-152 [PMID: 16771849 DOI: 10.1111/j.1365-2567.2006.02354.x]

34 **van de Donk NW**, Dhimolea E. Brentuximab vedotin. *MAbs* ; **4**: 458-465 [PMID: 22684302 DOI: 10.4161/mabs.20230]

35 **Cheng AL**, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. *J Clin Oncol* 2013; **31**: 4067-4075 [PMID: 24081937 DOI: 10.1200/JCO.2012.45.8372]

36 **Rao J**, Feng M, Qian X, Li G, Wang X, Zhang F, Lu L. Liver transplantation treating the patient with hepatic failure associated with sorafenib treatment: report of a case. *Hepatogastroenterology* 2013; **60**: 1317-1319 [PMID: 23933924 DOI: 10.5754/hge13185]

37 **Schramm C**, Schuch G, Lohse AW. Sorafenib-induced liver failure. *Am J Gastroenterol* 2008; **103**: 2162-2163 [PMID: 18796127 DOI: 10.1111/j.1572-0241.2008.01982\_19.x]

38 **Supekova L**, Supek F, Lee J, Chen S, Gray N, Pezacki JP, Schlapbach A, Schultz PG. Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. *J Biol Chem* 2008; **283**: 29-36 [PMID: 17951261 DOI: 10.1074/jbc.M703988200]

39 **Himmelsbach K**, Sauter D, Baumert TF, Ludwig L, Blum HE, Hildt E. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. *Gut* 2009; **58**: 1644-1653 [PMID: 19710032 DOI: 10.1136/gut.2009.182212]

40 **Hutson TE**, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin RA. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2010; **28**: 475-480 [PMID: 20008644 DOI: 10.1200/JCO.2008.21.6994]

41 **Escudier B**, Gore M. Axitinib for the management of metastatic renal cell carcinoma. *Drugs R D* 2011; **11**: 113-126 [PMID: 21679004 DOI: 10.2165/11591240-000000000-00000]

42 **Ripault MP**, Pinzani V, Fayolle V, Pageaux GP, Larrey D. Crizotinib-induced acute hepatitis: first case with relapse after reintroduction with reduced dose. *Clin Res Hepatol Gastroenterol* 2013; **37**: e21-e23 [PMID: 23182672 DOI: 10.1016/j.clinre.2012.10.003]

43 **Ikeda K**, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, Noji H, Ogawa K, Nakamura A, Ohira H, Sato Y, Maruyama Y. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. *Leuk Lymphoma* 2006; **47**: 155-157 [PMID: 16321842 DOI: 10.1080/14639230500236818]

44 **Kang BW**, Lee SJ, Moon JH, Kim SN, Chae YS, Kim JG, Hwang YJ, Sohn SK. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. *Int J Hematol* 2009; **90**: 383-387 [PMID: 19641858 DOI: 10.1007/s12185-009-0386-2]

45 **Wang YD**, Cui GH, You Y, Li M, Xia J, Hu Y. [Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy in patients with chronic myeloid leukemia: two cases report and literatures review]. *Zhonghua Xue Ye Xue Za Zhi* 2012; **33**: 743-746 [PMID: 23336229 DOI: 10.3760/cma.j.issn.0253-2727.2012.09.012]

46 **Lai GM**, Yan SL, Chang CS, Tsai CY. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. *World J Gastroenterol* 2013; **19**: 1318-1321 [PMID: 23483799 DOI: 10.3748/wjg.v19.i8.1318]

47 **Seggewiss R**, Loré K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. *Blood* 2005; **105**: 2473-2479 [PMID: 15572591 DOI: 10.1182/blood-2004-07-2527]

48 **Appel S**, Boehmler AM, Grünebach F, Müller MR, Rupf A, Weck MM, Hartmann U, Reichardt VL, Kanz L, Brümmendorf TH, Brossart P. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. *Blood* 2004; **103**: 538-544 [PMID: 14504105 DOI: 10.1182/blood-2003-03-0975]

49 **Castillo-Rama M**, Grande C, Martínez-Sanchez P, Olavarria E, Marín D, Paz-Artal E, Andrés A, Morales JM. [Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant]. *Nefrologia* 2009; **29**: 604-607 [PMID: 19936007 DOI: 10.3265/Nefrologia.2009.29.6.5346.en.full]

50 **Lin AY**, Fisher GA, So S, Tang C, Levitt L. Phase II study of imatinib in unresectable hepatocellular carcinoma. *Am J Clin Oncol* 2008; **31**: 84-88 [PMID: 18376233 DOI: 10.1097/COC.0b013e3181131db9]

51 **Grünwald V**, Weikert S, Pavel ME, Hörsch D, Lüftner D, Janni W, Geberth M, Weber MM. Practical management of everolimus-related toxicities in patients with advanced solid tumors. *Onkologie* 2013; **36**: 295-302 [PMID: 23689226 DOI: 10.1159/000350625]

52 **Teng CF**, Wu HC, Tsai HW, Shiah HS, Huang W, Su IJ. Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy. *Hepatology* 2011; **54**: 1199-1207 [PMID: 21735472 DOI: 10.1002/hep.24529]

53 **Mizuno S**, Yamagishi Y, Ebinuma H, Nakamoto N, Katahira M, Sasaki A, Sakamoto M, Suzuki H, Kanai T, Hibi T. Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier. *Clin J Gastroenterol* 2013; **6**: 188-192 [PMID: 23606919 DOI: 10.1007/s12328-013-0371-4]

54 **Sezgin Göksu S**, Bilal S, Coşkun HŞ. Hepatitis B reactivation related to everolimus. *World J Hepatol* 2013; **5**: 43-45 [PMID: 23383366 DOI: 10.4254/wjh.v5.i1.43.]

55 **Baselga J**, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2012; **366**: 520-529 [PMID: 22149876 DOI: 10.1056/NEJMoa1109653.]

56 **Casanovas T**, Argudo A, Peña-Cala MC. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports. *Transplant Proc* 2011; **43**: 2233-2236 [PMID: 21839242 DOI: 10.1016/j.transproceed.2011.05.028.]

57 **Casanovas T**, Argudo A, Peña-Cala MC. Everolimus in clinical practice in long-term liver transplantation: an observational study. *Transplant Proc* 2011; **43**: 2216-2219 [PMID: 21839237 DOI: 10.1016/j.transproceed.2011.06.015.]

58 **Choueiri TK**, Je Y, Sonpavde G, Richards CJ, Galsky MD, Nguyen PL, Schutz F, Heng DY, Kaymakcalan MD. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. *Ann Oncol* 2013; **24**: 2092-2097 [PMID: 23658373 DOI: 10.1093/annonc/mdt155]

59 **Matsumoto A**, Ichikawa T, Nakao K, Miyaaki H, Hirano K, Fujimito M, Akiyama M, Miuma S, Ozawa E, Shibata H, Takeshita S, Yamasaki H, Ikeda M, Kato N, Eguchi K. Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway. *J Gastroenterol* 2009; **44**: 856-863 [PMID: 19436942 DOI: 10.1007/s00535-009-0075-1]

60 **Miura Y**, Theriault RL, Naito Y, Suyama K, Shimomura A, Iwatani T, Miura D, Kawabata H, Kumada H, Takano T. The safety of chemotherapy for breast cancer patients with hepatitis C virus infection. *J Cancer* 2013; **4**: 519-523 [PMID: 23901352 DOI: 10.7150/jca.6231]

61 **Tamori A**, Kawajiri H, Takashima T, Motoyama H, Morikawa H, Enomoto M, Hirakawa K, Kawada N. Could trastuzumab suppress hepatitis C virus in a patient with chronic hepatitis and breast cancer? *Am J Gastroenterol* 2011; **106**: 1865-1866 [PMID: 21979218 DOI: 10.1038/ajg.2011.258]

62 **Lupberger J**, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. *Nat Med* 2011; **17**: 589-595 [PMID: 21516087 DOI: 10.1038/nm.2341]

63 **Diao J**, Pantua H, Ngu H, Komuves L, Diehl L, Schaefer G, Kapadia SB. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. *J Virol* 2012; **86**: 10935-10949 [PMID: 22855500 DOI: 10.1128/JVI.00750-12]

64 **Lupberger J**, Duong FH, Fofana I, Zona L, Xiao F, Thumann C, Durand SC, Pessaux P, Zeisel MB, Heim MH, Baumert TF. Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha. *Hepatology* 2013; **58**: 1225-1235 [PMID: 23519785 DOI: 10.1002/hep.26404]

65 **Nakamoto N**, Cho H, Shaked A, Olthoff K, Valiga ME, Kaminski M, Gostick E, Price DA, Freeman GJ, Wherry EJ, Chang KM. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. *PLoS Pathog* 2009; **5**: e1000313 [PMID: 19247441 DOI: 10.1371/journal.ppat.1000313]

66 **Minter S**, Willner I, Shirai K. Ipilimumab-induced hepatitis C viral suppression. *J Clin Oncol* 2013; **31**: e307-e308 [PMID: 23690418 DOI: 10.1200/JCO.2012.46.5831]

67 **Sharma A**, Thompson JA, Repaka A, Mehnert JM. Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. *J Clin Oncol* 2013; **31**: e370-e372 [PMID: 23775956 DOI: 10.1200/JCO.2012.47.1946]

**P-Reviewers:** Clement J, Mazzanti R, Shih WL, Raboni SM **S-Editor:** Qi Y

**L-Editor: E-Editor:**

**Table 1 Association of targeted therapies and hepatitis C virus reactivation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Targeted therapy** | **Increased HCV viral load** | **HCV Related Hepatic Flare** | **Liver Function test Follow up** | **HCV RNA Follow up** |
| Anti-CD Antibodies |  |  |  |  |
| Rituximab | Yes, in case series. | May cause, further studies are needed. | Yes | Yes, especially in high risk patients |
| Alemtuzumab | Yes, in one case report. | Yes, in one case report. | Yes | Yes |
| Brentixumab | No data in literature | No data in literature | No | No |
| Tyrosine kinase inhibitors: |
| Imatinib: | HBV reactivation in CML patients, the data related to HCV insufficient | No. (In HBV infected patients maybe) | Yes (DIH) | No |
| Sorafenib: | No, on the contrary in some cases sorafenib may have a suppressive effect on HCV viral load | No | No ( DIH) | No |
| Crizitonib: | US | US | Yes, may cause dose dependent hepatitis | No |
| PazopanibLapatinib | USNo | USNo | Yes ( DİH)Yes (DIH) | NoNo |
| mTOR Inhibitors: |  |  |  |  |
| Everolimus | Maybe. (In the literature, 2 cases of HBV reactivation) | Yes(In Phase 3 trial as a side effect) | Yes | No |
| Anti-Her2 Ab: |  |  |  |  |
| Trastuzumab: | No | No | No | No |
| Pertuzumab: | No | No | No | No |
| Anti-EGFR Therapies: |  |  |  |  |
| Cetuximab | US | US | No | No |
| Panitumumab | US | US | No | No |
| ImmunmodulatingAb: |  |  |  |  |
| Ipilimumab | No (Two cases of HCV infected patients were safely treated) | No | Yes (DIH) | No |

Ab: Antibodies; US: Unspecified; DIH: Drug induced hepatotoxicity; HCV: Hepatitis C virus.